PDCD1 and melanoma: Continued neoadjuvant trials are ongoing at a large scale, which is evident through a global analysis of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials demonstrating a high prevalence in melanoma-specific research [32].